Deuruxolitinib for Alopecia Areata

Deuruxolitinib, an oral JAK inhibitor, was approved by the FDA in July 2024 for treating severe alopecia areata (AA) in adults, marking it as the third oral JAK inhibitor for this condition alongside baricitinib and ritlecitinib. AA is an autoimmune disease affecting 2% of the US population, driven by CD8 T-cells and involving cytokines like interferon-gamma and interleukin-15, which rely on JAK signaling. The document reviews deuruxolitinib's mechanism of action, clinical efficacy, and safety profile in managing AA.